Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the s...
– The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-fr...
Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study sho...
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant ...
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about ...
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated nea...
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + G...
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for peopl...
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1 Patients with HER2-low s...
